Welcome to our dedicated page for InMed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InMed Pharmaceuticals Inc. filings document the regulatory record of a British Columbia pharmaceutical issuer with common shares listed on Nasdaq under INM. Its disclosures cover small-molecule drug development programs targeting CB1 and CB2 receptors, including INM-901 for Alzheimer's disease and programs in ocular and dermatological indications.
Recent filings include Current Reports on Form 8-K for financial results and business updates, material definitive agreements involving preferred investment options, at-the-market offering documentation, Nasdaq continued-listing compliance, shareholder voting matters, and exit or disposal activities related to BayMedica. The company's formal reports also address risk factors, capital structure, governance, and clinical or regulatory disclosures.
Private investment funds managed by ADAR1 Capital Management, LLC, a ten percent owner of InMed Pharmaceuticals, purchased 1,000 Common Shares on July 15, 2026 at $1.555 per share, increasing their indirect holdings to 801,000 shares. ADAR1 and Daniel Schneeberger may be deemed indirect owners but each disclaims beneficial ownership except for any pecuniary interest. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.
Vivo Opportunity–affiliated entities reported open-market purchases totaling 20,546 Common Shares of InMed Pharmaceuticals Inc. at $1.55 per share on July 14–16, 2026. The trades, made through Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., brought their holdings to 743,057 and 75,019 shares, respectively. Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, as general partners, disclaim beneficial ownership beyond their pecuniary interests.
InMed Pharmaceuticals Inc. entered into Amendment No. 1 to its Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. and two merger subsidiaries. The amendment clarifies the sequence of corporate actions, including a planned name change to “Mentari Therapeutics, Inc.” before closing, a redomestication from British Columbia to Nevada on the closing date before filing the certificate of merger, and any Nasdaq reverse split before the first merger effective time. It introduces a defined Company PIPE Amendment to enable potential additional pre-closing private placement financing for Mentari and clarifies how such financing affects the exchange ratio. It also confirms the combined mergers are intended to qualify as a tax “reorganization” under Section 368(a) of the Internal Revenue Code and removes a prior contingency about a possible Cayman redomestication. InMed and Mentari also announced that a Form S-4 with a preliminary joint proxy statement/prospectus has been filed with the SEC.
InMed Pharmaceuticals Inc. entered into Amendment No. 1 to its Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, refining key aspects of their previously announced all‑stock business combination. The amendment clarifies the sequencing of the contemplated steps, including that InMed will change its name to “Mentari Therapeutics, Inc.” before closing, redomesticate from British Columbia to Nevada on the closing date but before the merger is filed, and complete any required Nasdaq reverse split before the first merger effective time.
The amendment also introduces a defined Company PIPE Amendment to allow potential additional pre‑closing private placement financing for Mentari and sets out how such financing would affect the exchange ratio between the parties. In addition, it confirms the intended U.S. tax treatment, stating that the two merger steps are expected to form a single “reorganization” under Section 368(a) of the Internal Revenue Code, and removes a prior contingency regarding a possible redomestication to the Cayman Islands.
Separately, InMed filed a registration statement on Form S‑4 on July 2, 2026 containing a preliminary joint proxy statement/prospectus and management information circular for the proposed transaction, which has board approval at both companies and is targeted to close in the fourth quarter of 2026, subject to shareholder approvals, effectiveness of the Form S‑4 and other customary conditions.
InMed Pharmaceuticals Inc. reported that investment entities affiliated with Vivo Opportunity made a series of open-market purchases of its Common Shares. Over June 30 to July 2, 2026, Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Fund Holdings, L.P. together bought 6,551 shares at weighted average prices around $1.54–$1.55 per share in multiple transactions within stated price ranges. Following these purchases, Cayman Fund indirectly held 73,135 shares and Fund Holdings indirectly held 724,395 shares, with general partners Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC disclaiming beneficial ownership except for their pecuniary interest.
InMed Pharmaceuticals Inc. files a preliminary proxy statement/prospectus on Form S-4 to register securities in connection with a proposed merger with Mentari Therapeutics, Inc. The filing discloses an estimated Exchange Ratio of approximately 2.0606 InMed Common Shares per share of Mentari Common Stock (based on specified capitalization and an assumed InMed net cash at closing of $(3.6) million). Mentari entered into a Mentari Pre-Closing Financing for approximately $290.0 million.
Post-closing ownership is currently projected to be ~1.51% for pre-merger InMed securityholders and ~98.49% for former Mentari securityholders on a fully-diluted basis, subject to adjustments described in the Merger Agreement. The transaction contemplates a redomestication to Nevada, a proposed name change to Mentari Therapeutics, Inc., an anticipated Nasdaq ticker of MTRI, a proposed Reverse Stock Split, and issuance of Contingent Value Rights with a primary term to the second anniversary (extendable as described). Completion is conditioned on customary closing items, including Nasdaq confirmation of listing.
Vivo Opportunity funds reported significant stakes in InMed Pharmaceuticals Inc. and outlined their role in a pending merger. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC beneficially own 718,444 common shares, or 21.7% of InMed’s 3,314,063 shares outstanding as of May 4, 2026. Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC beneficially own 72,535 common shares, or 2.2% of the class.
The filing explains that on May 19, 2026, InMed agreed to acquire Mentari Therapeutics, Inc. through a two-step merger, with Mentari becoming an indirect wholly owned subsidiary. Certain investors, including the Vivo funds, also agreed to a pre-closing financing in which they will buy Mentari stock that will convert into InMed common shares at the same exchange ratio used in the merger. The Vivo funds state they acquired InMed shares in open-market purchases beginning May 19, 2026 and ending June 8, 2026, and that they hold the shares for investment purposes.
InMed Pharmaceuticals Inc. reported significant insider buying by entities associated with Vivo Opportunity. Over multiple open-market purchases from May 20 to June 8, 2026, Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. acquired a combined 249,227 common shares at prices generally between $1.42 and $1.75 per share. The funds’ general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, are listed as reporting persons but each disclaims beneficial ownership beyond its pecuniary interest.
InMed Pharmaceuticals Inc. reported initial insider holdings for several Vivo Opportunity investment entities. Vivo Opportunity Cayman Fund, L.P. indirectly holds 49,679 common shares, while Vivo Opportunity Fund Holdings, L.P. indirectly holds 492,073 common shares. The general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, each disclaim beneficial ownership except to the extent of their pecuniary interest.
InMed Pharmaceuticals Inc. has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq confirmed that the company’s common shares closed at or above $1.00 per share for 10 consecutive business days from May 19, 2026 through June 2, 2026.
This closes a prior deficiency notice InMed received in March 2026 after its shares traded below $1.00 for 30 consecutive business days. The company remains listed on Nasdaq and has disclosed the update via an 8-K and accompanying press release.